Previous post Next post

Novartis extends mid-term growth targets

Novartis is extending its medium-term outlook by one year. Over the period 2025-2030, the Swiss pharma giant aims to achieve annualised, currency-adjusted growth of around 5 to 6%, compared with more than 6% over the period 2024-2029. +Get the most important news from Switzerland in your inbox Management is aiming to restore the core operating margin to above 40% by 2029, once it has absorbed an impact of one to two basis points from the planned acquisition of Avidity Biosciences. Completion of this acquisition, worth some $12 billion, is scheduled for the first half of next year, the Basel-based firm said at its investor day. + Swiss pharma evaluates US trade deal The group has also revised upwards the annual commercial potential of its anti-cancer drugs Kisqali and Scemblix, to more than $10 billion from more than $8 billion and more than $4 billion from more than $3 billion respectively. The product portfolio now includes eight commercial assets with potential annual revenues of ... Full story here Are you the author?
About Swissinfo
Swissinfo
SWI swissinfo.ch – the international service of the Swiss Broadcasting Corporation (SBC). Since 1999, swissinfo.ch has fulfilled the federal government’s mandate to distribute information about Switzerland internationally, supplementing the online offerings of the radio and television stations of the SBC. Today, the international service is directed above all at an international audience interested in Switzerland, as well as at Swiss citizens living abroad.
Previous post See more for 3.) Swissinfo Business and Economy Next post
Tags: ,

Permanent link to this article: https://snbchf.com/2025/11/novartis-extends-mid-term-growth-targets/

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

This site uses Akismet to reduce spam. Learn how your comment data is processed.